Francis Hubler

USPTO Granted Patents = 17 (Patent Applications = 5)

CIPO Patents = 10 (Patent Applications = 5)

EPO Patents = 13 (Patent Applications = 18)

Average Co-Inventor Count = 4.5

ph-index = 5

Forward Citations = 46(Granted Patents)

Location History:

Hégenheim, FR (2011)
Alschwil, CH (2012)
Hegenheim, FR (2011 - 2016)
Allschwil, GB (2016)
Allschwil, CH (2012 - 2023)

Company Filing History:

14 out of 217

Actelion Pharmaceuticals Ltd

patents

3 out of 77

Idorsia Pharmaceuticals Ltd

patents

Years Active: 2011-2023

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11739070 - C5A receptor modulators (2023-08-29),

2. 11608341 - Substituted tetrahydropyrazolo[3,4-d]pyrimidines and tetrahydropyrazolo[4,3-d]pyrimidines as C5A receptor modulators (2023-03-21),

3. 9718774 - Indole carboxamide derivatives as P2X7 receptor antagonist (2017-08-01),

4. 9556117 - [object Object] (2017-01-31),

5. 9409917 - Heterocyclic amide derivatives as P2X7 receptor antagonists (2016-08-09),

6. 9388198 - [object Object] (2016-07-12),

7. 9388197 - Heterocyclic amide derivatives as P2X7 receptor antagonists (2016-07-12),

8. 9221832 - Heterocyclic amide derivatives as P2X7 receptor antagonists (2015-12-29),

9. 8664203 - Thiazole derivatives and their use as P2Y12 receptor antagonists (2014-03-04),

10. 8518912 - [object Object] (2013-08-27),

11. 8492555 - Salts of isobutyric acid (1 R*, 2R*, 4R*)-2-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-methyl-amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester (2013-07-23),

12. 8436205 - Tetrahydronaphthalene compounds (2013-05-07),

13. 8314253 - Bridged tetrahydronaphthalene derivatives (2012-11-20),

14. 8288385 - 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines (2012-10-16),

15. 8202885 - Bridged six-membered ring compounds (2012-06-19),

Title: The Innovative Contributions of Francis Hubler

Introduction

Francis Hubler is a notable inventor based in Allschwil, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of C5A receptor modulators. With a total of 17 patents to his name, Hubler's work has had a considerable impact on medical research and drug development.

Latest Patents

Hubler's latest patents focus on derivatives that serve as C5A receptor modulators. These inventions include compounds of formula (I), which are described in detail in his patent documentation. The patents emphasize the preparation of these compounds, their pharmaceutically acceptable salts, and their applications in pharmaceutical compositions. His work on substituted tetrahydropyrazolo[3,4-d]pyrimidines and tetrahydropyrazolo[4,3-d]pyrimidines further illustrates his innovative approach to drug development.

Career Highlights

Throughout his career, Hubler has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Actelion Pharmaceuticals Ltd and Idorsia Pharmaceuticals Ltd. His experience in these organizations has allowed him to collaborate on groundbreaking research and development projects.

Collaborations

Hubler has collaborated with esteemed colleagues in the field, including Dorte Renneberg and Kurt Hilpert. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Francis Hubler's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his role as a leading inventor. His work continues to influence the development of new therapeutic options in medicine.

This text is generated by artificial intelligence and may not be accurate.